Biocentric.ai empowers pharmaceutical innovation by harnessing AI to streamline drug discovery and accelerate breakthroughs that save lives.
Our interdisciplinary team combines AI expertise, computational biology, and biophysical insights to generate transformative therapeutic solutions. We are committed to addressing the inefficiencies in traditional drug discovery, delivering better drugs faster, and improving patient outcomes.
Case Studies
March 20, 2025______________
March 20, 2025
Novel Inhibitor Discovery for Influenza Virus Neuraminidase
March 20, 2025______________
March 20, 2025
Benchmarking a Novel In-Silico Pipeline for TYK2 Inhibitor Discovery
March 20, 2025______________
March 20, 2025
Selective TYK2 Inhibitor Discovery via Virtual Screening and ADMET Analysis
This end-to-end workflow illustrates how Biocentric’s proprietary platform, integrated with leading open-source and commercial toolkits, was applied in our TYK2 inhibitor discovery project. From an initial library of ~900 million compounds, our architecture enabled rapid triage, binding prediction, ADMET and selectivity filtering, and downstream validation-culminating in wet-lab confirmed hits.
Your message has been sent
biocentric.ai 